Trial · NCT03193216
The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus
NCT03193216, Phase 2, Completed, Medical University of South Carolina; results first posted 2023-03-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus. Trials, record NCT03193216. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03193216
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus
- NCT number
- NCT03193216
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 24 participants, actual
- Lead sponsor
- Medical University of South Carolina
- Conditions
- Barretts Esophagus With Dysplasia
- Interventions
- Alginates
- First posted
- 2017-06-20
- Last updated
- 2023-03-08
- Results first posted
- 2023-03-08
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Patients With Successful Eradication | 18 months | To compare the percentage of patients who achieved complete endoscopic eradication of dysplastic Barrett's Esophagus(BE) and non-dysplastic BE with the combination of PPI and liquid alginate solution vs. those treated with PPI alone within eighteen months from the start of treatment. |
| Secondary | Number of Treatments (Mean) | 18 months | To compare the number of treatment sessions required to achieve endoscopic eradication of dysplastic BE and complete eradication of all BE (dysplastic and non-dysplastic) in patients treated with the combination of PPI and liquid alginate solution vs. those treated with PPI alone.The minimum number of treatments would be 1 and maximum number of treatments in the 18 month period is 8. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Patients With Successful Eradication | 18 months | percentage of participants | NUMBER | |
| SECONDARY | Number of Treatments (Mean) | 18 months | number of treatment sessions | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Patients With Successful Eradication | Alginate Group | Percentage of patients with eradication of dysplasia | 45.5 | percentage of participants | |
| Percentage of Patients With Successful Eradication | Historical Control Group | Percentage of patients with eradication of dysplasia | 38.1 | percentage of participants | |
| Percentage of Patients With Successful Eradication | Alginate Group | Percentage of patients with eradication of all Barretts (dysplasic and non-dysplastic) | 36.4 | percentage of participants | |
| Percentage of Patients With Successful Eradication | Historical Control Group | Percentage of patients with eradication of all Barretts (dysplasic and non-dysplastic) | 19.04 | percentage of participants | |
| Number of Treatments (Mean) | Alginate Group | Average number of treatments to achieve eradication of dysplasia | 3.1 | Full Range 1 to 8 | number of treatment sessions |
| Number of Treatments (Mean) | Historical Control Group | Average number of treatments to achieve eradication of dysplasia | 3.88 | Full Range 1 to 8 | number of treatment sessions |
| Number of Treatments (Mean) | Alginate Group | Average number of treatments to achieve eradication of all Barrett's (dysplastic and non-dysplastic) | 3.75 | Full Range 1 to 8 | number of treatment sessions |
| Number of Treatments (Mean) | Historical Control Group | Average number of treatments to achieve eradication of all Barrett's (dysplastic and non-dysplastic) | 5 | Full Range 1 to 8 | number of treatment sessions |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Alginate Group | 24 | |
| Overall Study | STARTED | Historical Control Group | 21 | |
| Overall Study | COMPLETED | Alginate Group | 14 | |
| Overall Study | COMPLETED | Historical Control Group | 21 | |
| Overall Study | NOT COMPLETED | Alginate Group | 10 | |
| Overall Study | NOT COMPLETED | Historical Control Group | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Alginate Group | 0 | 22 |
| Total, all-cause mortality | Historical Control Group | 0 | 0 |
| Total, other adverse events | Alginate Group | 0 | 22 |
| Total, other adverse events | Historical Control Group | 0 | 0 |
| Total, serious adverse events | Alginate Group | 0 | 22 |
| Total, serious adverse events | Historical Control Group | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03193216
GET https://conductscience.org/api/trials/v1/NCT03193216/registered